- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
BTI’s net loss narrows in first quarter
Magnetic source imaging developer Biomagnetic Technologies ofSan Diego reported a lower net loss for its first quarter of 1997(end-December), due to lower R&D costs. Revenues for the quarterwere up slightly, but did not include any systems sales
Magnetic source imaging developer Biomagnetic Technologies ofSan Diego reported a lower net loss for its first quarter of 1997(end-December), due to lower R&D costs. Revenues for the quarterwere up slightly, but did not include any systems sales becausethe company is still awaiting the completion of a hardware upgradebefore it can record revenue from eight installations of its newMagnes 2500 Whole Head system.
For the quarter, BTI posted revenue of $317,000, compared with$195,000 in the same period the year before. The firm's net lossfor the most recent quarter stood at $2.1 million, compared with$3.1 million in the first quarter of 1996.
BTI has been hit hard by a delay in shipments of its Magnes 2500WH system, and was forced to restructure in December as a meansof conserving cash until it begins recognizing revenue from Magnesshipments (SCAN 2/5/97). That will happen once final customeracceptances are received following the installation of a hardwareupgrade that was not anticipated at the time of shipment, accordingto the company.
There are eight Magnes 2500 WH systems installed worldwide, andBTI's backlog as of Dec. 31 stood at $16.2 million, compared with$12.1 million the year before.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
